Press time:2016-06-03From:CR Pharm [ Font:BigMediumSmall]
(3 June 2016, Shanghai)– CR Pharma and WuXiAppTec today announced the establishment of a strategic partnership. According to the joint arrangement, CR Pharma will list WuXiAppTec as a strategic outsourcing partner and choose WuXiAppTec in priority for various medicine development. WuXiAppTec will provide a fully integrated services and technology platform for drug development.
Established in December 2000, WuXiAppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform. As an innovation-driven and customer-focused company, WuXiAppTec provides a broad and integrated portfolio of services throughout the drug R&D process.WuXi Biologics (a wholly-owned subsidiary of WuXiAppTec) is a leading Contract Discovery, Development and Manufacturing Organization (CDMO). Since established in 2008, WuXi biologics built the world’s first true concept to commercialization service and open-access technology platform for the biologics industry.
In the signing ceremony, CR pharma and WuXi Biologics also signed the first contract of CMC development of a biologic drug. After the ceremony, the two parties held a technical seminar of biological macromolecules and chemical drug, and explored the cooperation of next stage.
|
